Svenska

SIMRIS ALG AB CONFIRMS GRANTING OF JAPANESE PATENT COVERING THE MODIFICATION OF MICROCYSTINS

Report this content
  • The patent provides broad protection for a platform technology covering the modification of microcystins;  a novel ADC payload class with a unique, multimodal and universal mode of action.
  • The family of patents is now granted in Europe, UK, USA, Australia and Japan

Simris Alg AB (publ), a biologics company listed on the Swedish Nasdaq stock exchange and specialising in the extraction of high value biological compounds from microalgae and cyanobacteria, announced today that its patent for Microcystin-based ADCs has been granted in Japan.

Julian Read, CEO at Simris Alg AB, commented: “This approval means that the technology platform for our first class of ADC-payloads is now fully patent protected in the key markets including Europe, UK, USA, Australia and Japan. Whilst the status of our patent applications are still pending in China, Canada, Korea and India, we are confident that we be successful in these markets too. The granting of such patents is vital to our ability to generate a significant revenue stream from license agreements, sales of payloads, development milestone payments and ultimately royalties from commercial sales throughout the lifetime of the patent.”

Simris Alg AB Contact Details:
Julian Read
CEO Simris Alg AB
Email: ir@simris.com
Mobile: +46767888212
www.simrisalg.se

ABOUT SIMRIS ALG AB (PUBL):
Simris Alg is a biologics company identifying high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in skincare, nutrition, and biopharmaceuticals. The company sustainably grows microalgae and cyanobacteria on an industrial scale within its photobioreactor facility whereby conditions are optimized for production of these high-value compounds. Simris Alg's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664. Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.

Prenumerera

Dokument & länkar